Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02912845
Recruitment Status : Recruiting
First Posted : September 23, 2016
Last Update Posted : February 2, 2018
Kedrion S.p.A.
Information provided by (Responsible Party):
Kamada, Ltd.

Brief Summary:
The primary purpose of this study is to confirm the safety of KamRAB (Human Rabies Immunoglobulin) in children ages 0 months to <17 years, when administered as part of post-Rabies Exposure Prophylaxis (PEP).

Condition or disease Intervention/treatment Phase
Rabies Drug: KamRAB - HRIG Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : January 2017
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rabies

Arm Intervention/treatment
Experimental: 20 IU/kg KamRAB + Active Anti-Rabies Vaccine Drug: KamRAB - HRIG

Primary Outcome Measures :
  1. Frequency and severity of local and systemic adverse events occurring within 14 days of KamRAB treatment [ Time Frame: Within 14 days from treatment ]
  2. Frequency and severity of local and systemic SAEs occurring within 84 days of KamRAB treatment [ Time Frame: Within 84 days of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Healthy children (male and female) ages 0 months to <17 years.
  • Have been exposed or possibly exposed to rabies.
  • Are indicated to receive post-exposure prophylaxis (PEP) against rabies infection.
  • Have documented informed consent from the child's parent(s) or legal guardian(s) and assent from the child if appropriate.

Exclusion Criteria:

  • History of previous administration of rabies vaccine or human rabies immune globulin (HRIG)
  • Rabies exposure or possible rabies exposure more than seven days prior to initiation of PEP, or timing of exposure unknown

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02912845

United States, Arkansas
Little Rock, Arkansas, United States
Contact: Hobart-Porter    501-364-1050   
Sponsors and Collaborators
Kamada, Ltd.
Kedrion S.p.A.

Responsible Party: Kamada, Ltd. Identifier: NCT02912845     History of Changes
Other Study ID Numbers: KamRAB-004
First Posted: September 23, 2016    Key Record Dates
Last Update Posted: February 2, 2018
Last Verified: January 2018

Additional relevant MeSH terms:
Rhabdoviridae Infections
Mononegavirales Infections
RNA Virus Infections
Virus Diseases